Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of different treatment regimens in treating patients who have acute myeloid leukemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Research Council
• Treatments: Amsacrine; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Idarubicin; Mitoxantrone; Thioguanine; Tretinoin

Criteria

DISEASE CHARACTERISTICS:

• De novo or secondary acute myeloid leukemia of any morphologic type

• Acute promyelocytic leukemia also entered on MRC ATRA trial

• No blastic transformation of chronic myeloid leukemia

PATIENT CHARACTERISTICS:

Age:

• 15 to physiologic 59

• Patients for whom intensive therapy is considered inappropriate may be entered on protocol MRC-LEUK-AML11 or its successor

Performance status:

• Any status

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No concurrent active malignancy

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior cytotoxic chemotherapy for leukemia

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified